l e t t e r s MIC-CAP syndrome was recently described in six children, including one brother-sister pair, who all presented with small scattered capillary malformations, severe congenital microcephaly, early onset intractable epilepsy, profound global developmental delay, spastic quadriparesis, hypoplastic distal phalanges and poor growth 1-4 . Capillary malformations, sometimes referred to as port-wine stains, are nonregressing cutaneous vascular abnormalities 5 that are seen in a growing number of congenital syndromes linked to dysregulated RAS-MAPK (RAS-mitogen activated protein kinase) function; these are collectively termed 'RASopathies' . For example, mutations in RASA1, encoding p120-RasGAP, a negative regulator of the RAS pathway, have been found in patients with capillary malformationarteriovenous malformation syndrome 6 , and mutations in KRIT1, encoding a RAS-related protein 1A interactant, cause hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations 7 . Sequencing of RASA1 in two patients with MIC-CAP syndrome did not show any mutations, and sequencing of KRIT1 was not pursued 7 . Until now, the genetic mechanism responsible for this devastating disorder has been unknown.
l e t t e r s
Microcephaly-capillary malformation (MIC-CAP) syndrome is characterized by severe microcephaly with progressive cortical atrophy, intractable epilepsy, profound developmental delay and multiple small capillary malformations on the skin. We used whole-exome sequencing of five patients with MIC-CAP syndrome and identified recessive mutations in STAMBP, a gene encoding the deubiquitinating (DUB) isopeptidase STAMBP (STAM-binding protein, also known as AMSH, associated molecule with the SH3 domain of STAM) that has a key role in cell surface receptor-mediated endocytosis and sorting. Patient cell lines showed reduced STAMBP expression associated with accumulation of ubiquitin-conjugated protein aggregates, elevated apoptosis and insensitive activation of the RAS-MAPK and PI3K-AKT-mTOR pathways. The latter cellular phenotype is notable considering the established connection between these pathways and their association with vascular and capillary malformations. Furthermore, our findings of a congenital human disorder caused by a defective DUB protein that functions in endocytosis implicates ubiquitin-conjugate aggregation and elevated apoptosis as factors potentially influencing the progressive neuronal loss underlying MIC-CAP syndrome.
MIC-CAP syndrome was recently described in six children, including one brother-sister pair, who all presented with small scattered capillary malformations, severe congenital microcephaly, early onset intractable epilepsy, profound global developmental delay, spastic quadriparesis, hypoplastic distal phalanges and poor growth [1] [2] [3] [4] . Capillary malformations, sometimes referred to as port-wine stains, are nonregressing cutaneous vascular abnormalities 5 that are seen in a growing number of congenital syndromes linked to dysregulated RAS-MAPK (RAS-mitogen activated protein kinase) function; these are collectively termed 'RASopathies' . For example, mutations in RASA1, encoding p120-RasGAP, a negative regulator of the RAS pathway, have been found in patients with capillary malformationarteriovenous malformation syndrome 6 , and mutations in KRIT1, encoding a RAS-related protein 1A interactant, cause hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations 7 . Sequencing of RASA1 in two patients with MIC-CAP syndrome did not show any mutations, and sequencing of KRIT1 was not pursued 7 . Until now, the genetic mechanism responsible for this devastating disorder has been unknown.
We studied ten affected individuals from nine families with MIC-CAP syndrome ( Fig. 1 and Table 1 ). Brain magnetic resonance imaging scans of the affected individuals showed enlarged extra-axial spaces and other changes suggesting prenatal-onset cerebral atrophy with relative sparing of the cerebellum (Fig. 1a-c) . The gyral pattern was universally simplified and was associated with variable degrees of diffuse hypomyelination and hippocampal hypoplasia. We found Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly-capillary malformation syndrome l e t t e r s that all individuals with MIC-CAP syndrome had intractable epilepsy, severe developmental delay and profound intellectual disability. Other distinguishing features of MIC-CAP syndrome include infantile spasms, hypoplasia of the distal phalanges characterized by variable degrees of nail and toe hypoplasia and capillary malformations ( Fig. 1d-f) . The capillary malformations were striking in appearance and visible at birth in all patients. They were also generalized in distribution and tended to vary from small (2-3 mm) to large (15-20 mm) lesions. Interestingly, limited evidence suggests that the vascular anomalies are not restricted to skin capillary malformations; one patient (designated P3.1 in this study) had a cerebellar angioma 1 , and another patient (9.1) had possible vascular malformations of the liver as determined by ultrasound (data not shown).
To establish the genetic cause of MIC-CAP syndrome, we performed exome sequencing on DNA samples from five individuals ( Table 1 ) diagnosed with MIC-CAP syndrome. The two affected children in family 1, from nonconsanguineous parents, suggested a recessive mode of inheritance for this disorder. Therefore, we focused on identifying genes in which a maximal number of patients had two rare protein-altering variants that were absent from dbSNP131, the 1000 Genomes Project and 159 in-house control exomes. In four of the five patients studied by exome sequencing (P1.1, P1.2, P2.1 and P3.1), including the two siblings from family 1, we identified two variants in STAMBP in each individual (Fig. 2a, Supplementary Figs Table 2) . Co-segregation analysis confirmed an autosomal-recessive mode of inheritance in all families (Supplementary Fig. 3 ). Protein blot analysis of whole-cell extracts from patient-derived lymphoblastoid cell lines (LCLs) did not detect STAMBP expression in patient 1.2 (p.[Glu42Gly];[Arg178*]) (Fig. 2b) (Fig. 2b) .
We identified one coding mutation in STAMBP in patient 7.1. Analysis by protein blotting did not detect STAMBP expression in this individual (Fig. 2b) , and further sequencing of the gene revealed an intronic mutation (c.203+5G>A) believed to lead to an increase in skipping of the first coding exon ( Table 1 and Supplementary  Figs. 1b and 4a-d) .
In patient 5.1, we did not identify any coding mutations using exome sequencing. The depth of coverage across the exons of STAMBP did not suggest a deletion. However, analysis of SNP data from an Illumina Human Omni2.5 array, which contains 25 probes within STAMBP, suggested a 40-Mb region of copy-neutral homozygosity spanning STAMBP. Protein blotting revealed a severe reduction in STAMBP expression in this patient (Fig. 2b) , suggesting that P5.1 has MIC-CAP syndrome secondary to noncoding mutations in STAMBP. Sequencing of patient-derived complementary DNA showed the presence of a 108-bp pseudoexon containing a premature stop codon ( Supplementary Fig. 4e,f) . Deep intronic sequencing identified a homozygous mutation (c.1005+358A>G). Application of a computational model of splicing regulation 8 predicted that this mutation would activate a new donor site, as well as a cryptic AG acceptor site 114 bp upstream (P = 8.7 × 10 −7 , sign test). We believed that this mutation caused the leaky splicing of the full-length transcript and showed that patient cells have a threefold reduction of full-length transcript expression (Supplementary Figs. 1c and 4g) .
Sanger sequencing in patient 4.1 identified a homozygous stop mutation encoding p.Arg424*. Co-segregation analysis was not consistent with the suspected autosomal-recessive mode of inheritance in this nonconsanguineous family, as only the mother was heterozygous for the mutation causing p.Arg424*. We analyzed ten microsatellite markers spanning chromosome 2 and found all markers to be homozygous; a diagnostic array performed using DNA extracted from whole blood showed no evidence of copy number variation across chromosome 2. Therefore, we suspect that the mechanism of MIC-CAP syndrome in this patient is secondary to maternal isodisomy ( Supplementary Fig. 5 ). In summary, we identified two mutations in STAMBP in a total of ten patients: six missense variants, two nonsense mutations, two translational frameshift mutations predicted to cause a premature truncation of the STAMBP protein and three intronic mutations leading to alternative splicing of the STAMBP transcript (Fig. 2a) .
STAMBP is a JAMM-family DUB containing a microtubuleinteracting and transport (MIT) domain and a STAM-binding domain, both of which interact with the endosomal sorting and trafficking machinery ( Fig. 2a and Supplementary Fig. 6a ) [9] [10] [11] . STAMBP is recruited to the endosomal sorting complexes required for transport (ESCRTs), a group of distinct macromolecule assemblies that mediate the sorting and trafficking of ubiquitinated proteins from endosomes to lysosomes. STAMBP functions in regulating endosomal sorting of ESCRT machinery and ubiquitinated receptor cargo 9, [12] [13] [14] [15] [16] [17] . Endosomal sorting is a highly dynamic process that is fundamental to regulating protein homeostasis through the active regulation of receptor-mediated signal transduction and enabling processes such npg l e t t e r s as autophagy 18, 19 . Impaired ESCRT function is associated with the intracellular accumulation of ubiquitinated proteins. Brain lesions containing ubiquitinated protein aggregates have been noted in Stambp −/− mice 20 , suggesting this to be a probable mechanism influencing microcephaly and its progression in MIC-CAP syndrome. Consistent with this, we observed elevated amounts of conjugated-ubiquitin aggregates after short interfering RNA (siRNA)-mediated silencing of STAMBP in the human medullablastoma line T98G using indirect immunofluoresence with an antibody that specifically detects conjugated ubiquitin (FK2) and not free ubiquitin ( Fig. 3a and Supplementary Fig. 6b) . Notably, we also observed elevated amounts of conjugated-ubiquitin aggregates in several LCLs npg l e t t e r s from patients with STAMBP alterations compared to WT control LCLs after serum starvation (Fig. 3b) . This phenotype was reversed after stable lentiviral transduction of patient LCLs with STAMBP ( Supplementary Fig. 6c,d) . Furthermore, this phenotype was also associated with apoptosis induction, denoted by elevated amounts of cleaved caspase 3 ( Fig. 3c) and annexin V staining (Fig. 3d) in the LCLs of patients with STAMBP alterations compared to WT LCLs. STAMBP functions with the ESCRT machinery to facilitate autophagy. Autophagic flux can be monitored by detection of the expression of the autophagosome-associated phosphatidylethanolamine-conjugated microtubule-associated light chain 3 (LC3-II isoform) in the presence of the autophagy inhibitor bafilomycin A. Consistent with increased autophagic flux (that is, increased amounts of autophagosomes), we found elevated amounts of LC3-II in LCLs from patients with STAMBP alterations compared to WT control LCLs (Fig. 3e) .
ESCRT-mediated endocytosis of activated cell-surface receptors (for example, activated receptor tyrosine kinases or G protein-coupled receptors) controls receptor distribution and coordinates signal transduction amplitude and duration 17 . Endocytosed ubiquitinated receptors are either recycled to the cell surface or targeted for degradation in the lysosome, leading to the proteolysis and termination of receptor signaling 21 . STAMBP interacts with key components of receptor signaling pathways, such as Grb2 (Fig. 4a) 10, 22 . Considering the known role of STAMBP in regulating receptor-mediated endocytosis, sorting and trafficking, we investigated aspects of the interconnected RAS-MAPK and PI3K-AKT-mTOR signal transduction pathways in our MIC-CAP LCLs, as mutations in components of these networks are associated with congenital capillary malformation disorders 6, 7, 23 . We found elevated amounts of GTP-bound RAS (active RAS) in extracts from LCLs of patients with STAMBP alterations compared with WT LCLs, which is suggestive of elevated signaling through this pathway (Fig. 4b) . Similarly, we found elevated amounts of phosphorylated active phosphoinositol 3-kinase (PI3K) in cell extracts from LCLs from patients with STAMBP alterations relative to WT cells, even after serum starvation (Fig. 4c) . Collectively, these data suggest elevated and insensitive active signal transduction in these interconnected pathways associated with defective STAMBP in patient LCLs.
To further characterize signaling abnormalities, we examined the response of patient LCLs to serum starvation for both of these pathways using a selection of substrates. Serum starvation induced a substantial reduction in C-RAF phosphorylation at Ser338 in WT LCLs, consistent with inhibition of C-RAF activity under these conditions (Fig. 5a) . LCLs from patients with STAMBP alterations maintained C-RAF phosphorylation at Ser338 in the absence of serum, indicating persistent activation and insensitivity of this pathway. Further evidence suggesting insensitive signal transduction in the RAS-MAPK pathway in STAMBP-mutated LCLs is given by the relative insensitivity of these cells to the MEK1 and MEK2 (MEK1/2) inhibitor U0126. Active C-RAF phosphorylates and activates MEK1/2 kinase, which then phosphorylates and activates ERK1 and ERK2 (ERK1/2) (Fig. 4a) . We repeatedly found elevated amounts of phosphorylated ERK1/2 in exponentially growing STAMBP-mutated LCLs compared to WT LCLs after a short treatment (1 h) with U0126 ( Fig. 5b and  Supplementary Fig. 6e ). 26 , a JAMM (JAB1/MPN/MOV34) motif 12 , a nuclear localization signal (NLS) 11 and the distal ubiquitin recognition site (DUR) 27 . For c.279+5G>T in P2.1 (tissue from this patient was not available), a computational splicing model predicted the inclusion of an extra codon in exon 4 (P = 1.9 × 10 −9 , sign test). We validated this model using the known mutation in P7.1 (P = 1.9 × 10 −9 , sign test) (supplementary Fig. 1a) . Five out of six missense alterations are located in the MIT domain, which is required for the interaction of STAMBP with CHMP3, an ESCRT-III subunit 28 . The sixth alteration, p.Thr313Ile, located in the distal ubiquitin binding site within the JAMM domain, eliminates a hydrogen bond between the ubiquitin carbon backbone and STAMBP, probably decreasing ubiquitin binding to STAMBP (supplementary Fig. 2) . Two alterations were recurrent in multiple unrelated MIC-CAP families; p.Arg424*, detected in patients 3. npg l e t t e r s STAMBP-mutated LCLs under these robust inhibition conditions is further supportive of a hyperactive and insensitive RAS-MAPK pathway in these cells. Analysis of several endpoints in the PI3K-AKT-mTOR pathway under identical conditions indicated a similar insensitive activation of this pathway. Serum starvation of WT LCLs reduced the phosphorylation of AKT at Thr308, of the AKT-dependent Thr1462 of TSC2 and of Ser240 and Ser244 of S6 protein. This is consistent with pathway inactivation under these conditions in WT LCLs (Fig. 5c,d) . In contrast, LCLs from patients with STAMBP alterations maintained phosphorylation of all three proteins under these conditions (Fig. 5c,d) . Furthermore, stable lentiviral transduction of patient LCLs with STAMBP resulted in the reconstitution of a normal signaling response to serum starvation (Supplementary Fig. 6f) .
The RAS-MAPK and PI3K-AKT-mTOR pathways regulate crucial cellular processes, including cell growth, cell-cycle progression and differentiation. Disorders characterized by hyperactivity of the RAS-MAPK network, including Noonan and Costello syndromes, present with growth delay 24 . Considering the marked postnatal growth retardation and capillary abnormalities seen in MIC-CAP syndrome, hyperactive RAS-MAPK signaling may be a major biological Furthermore, as the PI3K-AKT-mTOR pathway also has a role in angiogenesis and vascularization, and considering the interconnectivity between these networks (Fig. 4a) , it is possible that the combined insensitive activation of both these networks may contribute to the MIC-CAP phenotype. In summary, we identify mutations in STAMBP in MIC-CAP syndrome, a recently described severe developmental disorder. Analysis of LCLs from patients with MIC-CAP syndrome demonstrated elevated ubiquitin-conjugated protein aggregation and apoptosis activation. These data are consistent with elevated ubiquitin-conjugated protein aggregate-induced progressive apoptosis as a potential underlying mechanism for the microcephaly in this disorder. This is consistent with brain imaging and human pathological analysis of MIC-CAP syndrome 1 and of the knockout mouse model of Stambp 25 . Furthermore, we document elevated autophagosome content and active and insensitive RAS-MAPK and PI3K-AKT-mTOR pathways as previously unidentified consequences of defective STAMBP, potentially contributing to the vasculature and growth characteristics of MIC-CAP syndrome. This work presents the first example, to our knowledge, of a human disorder caused by a congenitally defective DUB isopeptidase functioning in the endocytosis pathway, providing important new insights into the pathophysiology of human microcephaly and capillary malformation.
URLs. National Heart, Lung, and Blood Institute (NHLBI) Exome variant server, http://evs.gs.washington.edu/EVS/; FASTX-Toolkit, http://hannonlab.cshl.edu/fastx_toolkit/; Picard tools, http://picard. sourceforge.net/; SAMtools, http://samtools.sourceforge.net/.
MeTHODS
Methods and any associated references are available in the online version of the paper. (Fig. 4a) . Cells were harvested, and whole-cell extracts were probed for phosphorylation of ERK1/2 (pERK1/2), which is mediated by MEK. Insensitivity to this treatment (as measured by relative amounts of pERK1/2 remaining after treatment with the MEK inhibitor) would reflect the magnitude and intensity of signal transduction from RAF to MEK to ERK (Fig. 4a) . Residual pERK1/2 (Thr202 and Tyr204) signal (MEK-dependent phosphorylation) was seen in MIC-CAP LCLs in contrast to WT LCLs. This phenotype is underscored after titration of U0126 in various MIC-CAP LCLs compared to WT LCLs (supplementary Fig. 6e) . Collectively, these data indicate a greater strength of MEK1/2 activity in MIC-CAP LCLs compared to WT cells. (c) Serum starvation (24 h) reduces phosphorylation (activation) of AKT at Thr308 (pAKT) and of TSC2 at Thr1462 (pTSC2) and AKT-dependent inhibitory phosphorylation of TSC2 in WT LCLs in contrast to LCLs from P7.1, P1.1 and P3.1. The TSC1 and TSC2 complex is the principal negative regulator of the mTOR kinase complex (Fig. 4a) . These data are consistent with active signal transduction from PI3K-AKT-mTOR in MIC-CAP cells under these conditions. (d) S6 protein is phosphorylated by S6 kinase in an mTOR-dependent fashion (Fig. 4a) . Consistent with active signal transduction in this pathway under serum starvation conditions, LCLs from P7.1 and P1.1 maintained S6 phosphorylation (p-S6) at Ser240 and Ser244 in contrast to WT LCLs.
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